Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 5Terminated 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Thoracic 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 5Carcinoma, Non-Small-Cell Lung 5Melanoma 4Ovarian Neoplasms 3Carcinoma, Transitional Cell 3Small Cell Lung Carcinoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms 2Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Solid Tumor 1Skin Neoplasms 1Mesothelioma 1Lung Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1

Interventions

Carboplatin 44Paclitaxel 43liposomal doxorubicin 23Topotecan 19Gemcitabine 18pembrolizumab 17Cyclophosphamide 17Bevacizumab 16Cisplatin 12niraparib 9olaparib 8fludarabine 7Taxes 7Docetaxel 7aldesleukin 6Nivolumab 6Doxorubicin 61-dodecylpyridoxal 6oregovomab 5fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5rucaparib 4durvalumab 4avelumab 4Surgical Procedures, Operative 4Melphalan 4Ipilimumab 4Interleukin-2 4Etoposide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Ovarian Neoplasms × epacadostat × Clear all
NCT03277352 2021-07-22

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Incyte Corporation

Phase 1/2 Terminated
10 enrolled 14 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02575807 2019-04-04

SEASCAPE

Aduro Biotech, Inc.

Phase 1/2 Terminated
35 enrolled 20 charts
Gynecologic

Ovarian Neoplasms

NCT01685255 2019-03-11

A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

Incyte Corporation

Phase 2 Terminated
83 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡